Clinical Study Transparency

Lilly has a history of commitment to transparency of our clinical studies. In 2004, Lilly became the first company to voluntarily disclose the initiation of our clinical studies and post study results in a publicly available registry. Since the start of 2014, Lilly has enhanced our transparency initiatives in alignment with the PhRMA/EFPIA Principles for Responsible Clinical Trial Data Sharing. Lilly recognizes that responsible sharing of clinical study data has the ability to enhance public health while safeguarding the privacy of patients, respecting the integrity of national regulatory systems, and maintaining incentives for investments in biomedical research.

For more information on the aspects of our data and information sharing process, please see the following links:

Please enable your browser's JavaScript setting in order to access this site